HRP20182199T1 - Kruti pripravci koji sadrže tofogliflozin i postupak za njihovu proizvodnju - Google Patents

Kruti pripravci koji sadrže tofogliflozin i postupak za njihovu proizvodnju

Info

Publication number
HRP20182199T1
HRP20182199T1 HRP20182199TT HRP20182199T HRP20182199T1 HR P20182199 T1 HRP20182199 T1 HR P20182199T1 HR P20182199T T HRP20182199T T HR P20182199TT HR P20182199 T HRP20182199 T HR P20182199T HR P20182199 T1 HRP20182199 T1 HR P20182199T1
Authority
HR
Croatia
Prior art keywords
tofogliflozine
procedure
production
preparations containing
solid preparations
Prior art date
Application number
HRP20182199TT
Other languages
English (en)
Croatian (hr)
Inventor
Kenta Wada
Tomoaki Hirayama
Kenichi Sakai
Shiho YOSHIMURA
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Seiyaku Kabushiki Kaisha filed Critical Chugai Seiyaku Kabushiki Kaisha
Publication of HRP20182199T1 publication Critical patent/HRP20182199T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20182199TT 2013-12-27 2014-12-26 Kruti pripravci koji sadrže tofogliflozin i postupak za njihovu proizvodnju HRP20182199T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013273060 2013-12-27
EP14874030.1A EP3087989B1 (en) 2013-12-27 2014-12-26 Solid preparations comprising tofogliflozin and method for producing the same
PCT/JP2014/084561 WO2015099139A1 (ja) 2013-12-27 2014-12-26 トホグリフロジンを含有する固形製剤及びその製造方法

Publications (1)

Publication Number Publication Date
HRP20182199T1 true HRP20182199T1 (hr) 2019-02-22

Family

ID=53478978

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20182199TT HRP20182199T1 (hr) 2013-12-27 2014-12-26 Kruti pripravci koji sadrže tofogliflozin i postupak za njihovu proizvodnju

Country Status (21)

Country Link
US (2) US10231930B2 (enExample)
EP (2) EP3087989B1 (enExample)
JP (5) JP6513030B2 (enExample)
KR (2) KR102395687B1 (enExample)
CN (2) CN113058038B (enExample)
AU (1) AU2014370847B2 (enExample)
BR (1) BR112016013164B1 (enExample)
CA (1) CA2934832C (enExample)
DK (1) DK3087989T3 (enExample)
ES (1) ES2704065T3 (enExample)
HR (1) HRP20182199T1 (enExample)
HU (1) HUE041983T2 (enExample)
LT (1) LT3087989T (enExample)
MX (2) MX370342B (enExample)
PL (1) PL3087989T3 (enExample)
PT (1) PT3087989T (enExample)
RU (1) RU2700164C2 (enExample)
SI (1) SI3087989T1 (enExample)
TR (1) TR201821042T4 (enExample)
TW (2) TWI774159B (enExample)
WO (1) WO2015099139A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014KN02423A (enExample) 2006-04-07 2015-05-01 Vertex Pharma
DK3087989T3 (en) * 2013-12-27 2019-03-25 Chugai Pharmaceutical Co Ltd PHARMACEUTICAL COMPOSITIONS COMPREHENSIVE TOFOGLIFLOZINE AND PROCEDURES FOR PRODUCING THEREOF
CN108640958B (zh) * 2017-05-05 2021-03-30 镇江圣安医药有限公司 异苯并呋喃衍生物、其药物组合物和制剂以及用途
CN107811983A (zh) * 2017-12-04 2018-03-20 威海贯标信息科技有限公司 一种托格列净组合物
CN107759649A (zh) * 2017-12-12 2018-03-06 威海贯标信息科技有限公司 一种托格列净新晶型
JP2022146628A (ja) * 2021-03-22 2022-10-05 旭化成株式会社 錠剤及びその製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56145214A (en) 1980-04-11 1981-11-11 Taiho Yakuhin Kogyo Kk Ubidecarenone tablet
JP2626975B2 (ja) 1987-03-30 1997-07-02 エーザイ株式会社 低融点油性物質含有錠剤
ES2082723B1 (es) 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
JPH10287561A (ja) 1997-04-11 1998-10-27 Taisho Pharmaceut Co Ltd イブプロフェン配合固形製剤及びその製造方法
JP2000239185A (ja) 1999-02-16 2000-09-05 Taisho Pharmaceut Co Ltd 医薬組成物
US8507000B2 (en) 2003-05-06 2013-08-13 Nostrum Pharmaceuticals, Inc. Controlled release formulation of erythromycin derivatives
JP2005104934A (ja) 2003-10-01 2005-04-21 Eisai Co Ltd 新規組成物及びその製造方法
JP4997741B2 (ja) 2004-11-12 2012-08-08 大正製薬株式会社 低融点薬物含有粉粒体及びその製造方法
TW200637869A (en) * 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
PE20090185A1 (es) * 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
JP4072195B2 (ja) 2007-10-18 2008-04-09 キッセイ薬品工業株式会社 速放性経口医薬組成物
TW201011043A (en) * 2008-06-20 2010-03-16 Chugai Pharmaceutical Co Ltd Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
US20110014284A1 (en) * 2009-02-13 2011-01-20 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
WO2012115249A1 (ja) 2011-02-25 2012-08-30 中外製薬株式会社 スピロケタール誘導体の結晶
EA201301354A1 (ru) 2011-06-03 2014-05-30 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы sglt-2, предназначенные для лечения метаболических нарушений у пациентов, леченных нейролептиками
PL2981269T3 (pl) * 2013-04-04 2024-02-05 Boehringer Ingelheim Vetmedica Gmbh Leczenie zaburzeń metabolicznych u zwierząt koniowatych
DK3087989T3 (en) * 2013-12-27 2019-03-25 Chugai Pharmaceutical Co Ltd PHARMACEUTICAL COMPOSITIONS COMPREHENSIVE TOFOGLIFLOZINE AND PROCEDURES FOR PRODUCING THEREOF

Also Published As

Publication number Publication date
KR20160101719A (ko) 2016-08-25
JP2022116267A (ja) 2022-08-09
US10231930B2 (en) 2019-03-19
JPWO2015099139A1 (ja) 2017-03-23
BR112016013164B1 (pt) 2022-07-26
MX2019008865A (es) 2019-09-13
JP6759390B2 (ja) 2020-09-23
HK1224221A1 (zh) 2017-08-18
TR201821042T4 (tr) 2019-01-21
ES2704065T3 (es) 2019-03-14
HUE041983T2 (hu) 2019-06-28
AU2014370847A1 (en) 2016-06-16
US10398653B2 (en) 2019-09-03
CN105828826B (zh) 2021-04-06
RU2700164C2 (ru) 2019-09-13
EP3087989A1 (en) 2016-11-02
PT3087989T (pt) 2019-02-26
RU2016130602A (ru) 2018-02-01
WO2015099139A1 (ja) 2015-07-02
CA2934832A1 (en) 2015-07-02
CN113058038A (zh) 2021-07-02
DK3087989T3 (en) 2019-03-25
SI3087989T1 (sl) 2019-03-29
KR20210082557A (ko) 2021-07-05
JP2020203918A (ja) 2020-12-24
JP2019112424A (ja) 2019-07-11
LT3087989T (lt) 2019-02-11
TW202126311A (zh) 2021-07-16
RU2016130602A3 (enExample) 2018-06-08
US20190151248A1 (en) 2019-05-23
KR102395687B1 (ko) 2022-05-06
MX2016008527A (es) 2016-09-13
PL3087989T3 (pl) 2019-07-31
CN105828826A (zh) 2016-08-03
MX390480B (es) 2025-03-20
US20160324786A1 (en) 2016-11-10
JP6513030B2 (ja) 2019-05-15
TWI715523B (zh) 2021-01-11
TWI774159B (zh) 2022-08-11
EP3482748A1 (en) 2019-05-15
EP3087989A4 (en) 2017-09-20
JP2024063140A (ja) 2024-05-10
CN113058038B (zh) 2024-01-12
CA2934832C (en) 2022-03-15
EP3087989B1 (en) 2018-12-19
MX370342B (es) 2019-12-10
TW201609194A (zh) 2016-03-16
AU2014370847B2 (en) 2020-02-20
BR112016013164A2 (enExample) 2017-08-08

Similar Documents

Publication Publication Date Title
IL276106A (en) Garp-binding proteins and their uses
HRP20181302T1 (hr) Terapija za obnavljanje mikrobiota (mrt), pripravci i postupci proizvodnje
DK3033102T3 (da) Peptidkonjugerede partikler
HRP20181580T1 (hr) Pripravci cftr irnk i povezani postupci i upotrebe
DK3043784T3 (da) Arylethere og anvendelser deraf
IL256260B (en) Treprostinil derivatives and compositions and uses thereof
BR112015028459A2 (pt) composições e comestíveis
DOS2013000297S (es) Brazalete
DK3052516T3 (da) PCV2-ORF2-proteinvariant og viruslignende partikler sammensat deraf
DK3058936T3 (da) Peptidsammensætning og anvendelser deraf
DK2962100T3 (da) Tuberkulosebiomarkører og anvendelser deraf
EP2983661C0 (en) OXABICYCLOHEPTANE AND OXABICYCLOHEPTENE FORMULATIONS
HUE060909T2 (hu) Mûtrágya készítmények
DK2956410T3 (da) Kompositsilicium- eller komposittinpartikler
IL282430A (en) Anti-cancer agents and preparation thereof
SI2991633T1 (sl) Terapija za bakteriofagi
HRP20181122T1 (hr) Postupak za pripremu jopamidola
HRP20182173T8 (hr) Duhanski materijal i njegova obrada
HRP20182199T1 (hr) Kruti pripravci koji sadrže tofogliflozin i postupak za njihovu proizvodnju
HRP20181507T1 (hr) Modificirana sulfamidaza i njena proizvodnja
EP3048883C0 (en) PESTICIDE COMPOSITION AND ASSOCIATED PROCESS
DK3003401T3 (da) Farmaceutisk præparat
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
FR3007291B1 (fr) Composition cicatrisante et utlisation
HRP20171888T1 (hr) Farmaceutski pripravci